FOXC2 promotes epithelial–mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells

被引:0
作者
Yuwen He
Hui Xie
Pengjiu Yu
Shunjun Jiang
Li Wei
机构
[1] The First Affiliated Hospital of Guangzhou Medical University,Department of Pharmacy
来源
Cancer Chemotherapy and Pharmacology | 2018年 / 82卷
关键词
FOXC2; Non-small cell lung cancer; Epithelial–mesenchymal transition; Cisplatin resistance; Snail;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1049 / 1059
页数:10
相关论文
共 301 条
[1]  
Siegel RL(2016)Cancer statistics, 2016 CA Cancer J Clin 66 7-30
[2]  
Miller KD(2016)Chemotherapy resistance in lung cancer Adv Exp Med Biol 893 189-209
[3]  
Jemal A(2018)Epithelial mesenchymal transition in tumor metastasis Annu Rev Pathol 13 395-412
[4]  
Kim ES(2012)Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer Cancer Res Treat 44 151-156
[5]  
Mittal V(2015)Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance Nature 527 472-476
[6]  
Nurwidya F(2010)EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer Oncogene 29 4741-4751
[7]  
Takahashi F(2017)ZEB1 mediates drug resistance and EMT in p300-deficient CRC J Cancer 8 1453-1459
[8]  
Murakami A(2004)Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells Oncogene 23 474-482
[9]  
Takahashi K(2014)Epithelial–mesenchymal transition and drug resistance: role, molecular mechanisms, and therapeutic strategies Oncol Res Treat 37 584-589
[10]  
Fischer KR(2018)Emerging roles and mechanisms of FOXC2 in cancer Clin Chim Acta 479 84-93